103 related articles for article (PubMed ID: 32492016)
1. [High Expression Level of SP1, CSF1R, and PAK1 Correlates with Sensitivity of Leukemia Cells to the Antibiotic Mithramycin].
Vagapova ER; Lebedev TD; Tikhonova AD; Goikhman BV; Ivanenko KA; Spirin PV; Prassolov VS
Mol Biol (Mosk); 2020; 54(3):522-528. PubMed ID: 32492016
[TBL] [Abstract][Full Text] [Related]
2. CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.
Edwards DK; Watanabe-Smith K; Rofelty A; Damnernsawad A; Laderas T; Lamble A; Lind EF; Kaempf A; Mori M; Rosenberg M; d'Almeida A; Long N; Agarwal A; Sweeney DT; Loriaux M; McWeeney SK; Tyner JW
Blood; 2019 Feb; 133(6):588-599. PubMed ID: 30425048
[TBL] [Abstract][Full Text] [Related]
3. Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia.
Biethahn S; Alves F; Wilde S; Hiddemann W; Spiekermann K
Exp Hematol; 1999 May; 27(5):885-94. PubMed ID: 10340405
[TBL] [Abstract][Full Text] [Related]
4. SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.
Alachkar H; Santhanam R; Maharry K; Metzeler KH; Huang X; Kohlschmidt J; Mendler JH; Benito JM; Hickey C; Neviani P; Dorrance AM; Anghelina M; Khalife J; Tarighat SS; Volinia S; Whitman SP; Paschka P; Hoellerbauer P; Wu YZ; Han L; Bolon BN; Blum W; Mrózek K; Carroll AJ; Perrotti D; Andreeff M; Caligiuri MA; Konopleva M; Garzon R; Bloomfield CD; Marcucci G
J Clin Invest; 2014 Apr; 124(4):1512-24. PubMed ID: 24590286
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts.
Previdi S; Malek A; Albertini V; Riva C; Capella C; Broggini M; Carbone GM; Rohr J; Catapano CV
Gynecol Oncol; 2010 Aug; 118(2):182-8. PubMed ID: 20452660
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma.
Tornin J; Martinez-Cruzado L; Santos L; Rodriguez A; Núñez LE; Oro P; Hermosilla MA; Allonca E; Fernández-García MT; Astudillo A; Suarez C; Morís F; Rodriguez R
Oncotarget; 2016 May; 7(21):30935-50. PubMed ID: 27105533
[TBL] [Abstract][Full Text] [Related]
7. Sp1 coordinately regulates de novo lipogenesis and proliferation in cancer cells.
Lu S; Archer MC
Int J Cancer; 2010 Jan; 126(2):416-25. PubMed ID: 19621387
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide modulation of gene transcription in ovarian carcinoma cells by a new mithramycin analogue.
Vizcaíno C; Núñez LE; Morís F; Portugal J
PLoS One; 2014; 9(8):e104687. PubMed ID: 25110883
[TBL] [Abstract][Full Text] [Related]
9. Decitabine and vitamin D3 differentially affect hematopoietic transcription factors to induce monocytic differentiation.
Koschmieder S; Agrawal S; Radomska HS; Huettner CS; Tenen DG; Ottmann OG; Berdel WE; Serve HL; Müller-Tidow C
Int J Oncol; 2007 Feb; 30(2):349-55. PubMed ID: 17203216
[TBL] [Abstract][Full Text] [Related]
10. Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway.
Zhang Y; Chen HX; Zhou SY; Wang SX; Zheng K; Xu DD; Liu YT; Wang XY; Wang X; Yan HZ; Zhang L; Liu QY; Chen WQ; Wang YF
Mol Cancer; 2015 Mar; 14():56. PubMed ID: 25890196
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of p53-mediated transcriptional responses by mithramycin A.
Koutsodontis G; Kardassis D
Oncogene; 2004 Dec; 23(57):9190-200. PubMed ID: 15489892
[TBL] [Abstract][Full Text] [Related]
12. A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor.
Bendel AE; Shao Y; Davies SM; Warman B; Yang CH; Waddick KG; Uckun FM; Perentesis JP
Leuk Lymphoma; 1997 Apr; 25(3-4):257-70. PubMed ID: 9168436
[TBL] [Abstract][Full Text] [Related]
13. GC-rich sequences in the 5-lipoxygenase gene promoter are required for expression in Mono Mac 6 cells, characterization of a novel Sp1 binding site.
Dishart D; Schnur N; Klan N; Werz O; Steinhilber D; Samuelsson B; Rådmark O
Biochim Biophys Acta; 2005 Dec; 1738(1-3):37-47. PubMed ID: 16413224
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of ZFAS1 suppresses the progression of acute myeloid leukemia by regulating microRNA-150/Sp1 and microRNA-150/Myb pathways.
Gan S; Ma P; Ma J; Wang W; Han H; Chen L; Li X; Wu F; Sun H
Eur J Pharmacol; 2019 Feb; 844():38-48. PubMed ID: 30502345
[TBL] [Abstract][Full Text] [Related]
15. PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.
Pandolfi A; Stanley RF; Yu Y; Bartholdy B; Pendurti G; Gritsman K; Boultwood J; Chernoff J; Verma A; Steidl U
Blood; 2015 Aug; 126(9):1118-27. PubMed ID: 26170031
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer.
Yuan P; Wang L; Wei D; Zhang J; Jia Z; Li Q; Le X; Wang H; Yao J; Xie K
Cancer; 2007 Dec; 110(12):2682-90. PubMed ID: 17973266
[TBL] [Abstract][Full Text] [Related]
17. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
Kurtz SE; Eide CA; Kaempf A; Khanna V; Savage SL; Rofelty A; English I; Ho H; Pandya R; Bolosky WJ; Poon H; Deininger MW; Collins R; Swords RT; Watts J; Pollyea DA; Medeiros BC; Traer E; Tognon CE; Mori M; Druker BJ; Tyner JW
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):E7554-E7563. PubMed ID: 28784769
[TBL] [Abstract][Full Text] [Related]
18. Sp1 mediates phorbol ester (PMA)-induced expression of membrane-bound guanylyl cyclase GC-A in human monocytic THP-1 cells.
Mitkiewicz M; Bac B; Kuropatwa M; Kurowska E; Matuszyk J; Siednienko J
Acta Biochim Pol; 2018; 65(3):409-414. PubMed ID: 29959857
[TBL] [Abstract][Full Text] [Related]
19. Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo.
Blume SW; Snyder RC; Ray R; Thomas S; Koller CA; Miller DM
J Clin Invest; 1991 Nov; 88(5):1613-21. PubMed ID: 1834700
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A.
Jia Z; Zhang J; Wei D; Wang L; Yuan P; Le X; Li Q; Yao J; Xie K
Cancer Res; 2007 May; 67(10):4878-85. PubMed ID: 17510417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
